DanielFHayesMD

Oncology • Ann Arbor, MI

Professor of Medicine, University Mich Medical School

Join to view full profile

Dr. Hayes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hayes' full profile

Already have an account?

Office
1500 E Medical Center Dr
Ann Arbor, MI 48109
Phone+1 734-936-4000

Summary

Medical Oncologist with focus on Breast Cancer at University of Michigan Rogel Cancer Center

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1982 - 1984
University of Texas Southwestern Medical CenterInternship, Internal Medicine, 1979 - 1980
Indiana University School of MedicineClass of 1979

Certifications & Licensure

MA State Medical License 1982 - 2023
MI State Medical License 2001 - 2023
DC State Medical License 1996 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Join now to see all

Clinical Trials

Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 1999 Dec 01
Completed
Phase 2
Aromatase Inhibitor Clinical Trial Start of enrollment: 2005 Jan 01
Unknown status
A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism Start of enrollment: 2005 Nov 01
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313 Start of enrollment: 2009 Jan 01
Completed
Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial Start of enrollment: 2011 Nov 01
Unknown status
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
Join now to see all

Publications & Presentations

PubMed

249 citations
Considerations in the development of circulating tumor cell technology for clinical use
David R. Parkinson, Nicholas C. Dracopoli, Brenda Gumbs Petty, Carolyn C. Compton, Massimo Cristofanilli
Journal of Translational Medicine. 2012-07-02
1498 citations
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
Lyndsay Harris, Herbert A. Fritsche, Robert G. Mennel, Larry Norton, Peter M. Ravdin
Journal of Clinical Oncology. 2007-11-20
837 citations
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
S. Eva Singletary, Craig Allred, Pandora Ashley, Lawrence W. Bassett, Donald A. Berry
Journal of Clinical Oncology. 2002-09-01

Journal Articles

An International Multicenter Study to Evaluate Reproducibility of Automated Scoring for Assessment of Ki67 in Breast Cancer
Richard Levenson, David L Rimm, Daniel F Hayes, Chad Galderisi, Liron Pantanowitz, Nature
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Matthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine

Other

Systemic treatment for metastatic breast cancer: General principles
Hayes DF
http://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-general-principles
UpToDate, Wolters Kluwer Health - 2012-12-06
Tumor node metastasis (TNM) staging classification for breast cancer
Hayes DF
http://www.uptodate.com/contents/tumor-node-metastasis-tnm-staging-classification-for-breast-cancer
UpToDate, Wolters Kluwer Health - 2012-04-23
Measurement of prognostic factors in breast cancer
Hayes DF
http://www.uptodate.com/contents/measurement-of-prognostic-factors-in-breast-cancer
UpToDate, Wolters Kluwer Health - 2012-10-18
HER2 and predicting response to therapy in breast cancer
Hayes DF, Yamauchi H
http://www.uptodate.com/contents/her2-and-predicting-response-to-therapy-in-breast-cancer
UpToDate, Wolters Kluwer Health - 2012-10-04
Management of locoregional recurrence of breast cancer after mastectomy
Hayes DF, Hirsch A, Kachnic LA, Sabel MS
http://www.uptodate.com/contents/management-of-locoregional-recurrence-of-breast-cancer-after-mastec
UpToDate, Wolters Kluwer Health - 2013-01-17
Systemic treatment for metastatic breast cancer: Combination chemotherapy
Hayes DF
http://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-combination-chemoth
UpToDate, Wolters Kluwer Health - 2012-05-30
Systemic treatment for metastatic breast cancer: Molecular targeted therapy
Hayes DF
http://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-molecular-targeted-
UpToDate, Wolters Kluwer Health - 2013-04-01
Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen
Hayes DF
http://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-selection-of-chemot
UpToDate, Wolters Kluwer Health - 2012-05-30
Systemic treatment for metastatic breast cancer: Single agent chemotherapy
Hayes DF
http://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-single-agent-chemot
UpToDate, Wolters Kluwer Health - 2012-08-08
Join now to see all

Press Mentions

David Smith Retires with a Legacy of Compassionate Patient CareOctober 16th, 2024
ASCO Remembers Saul a. Rosenberg, MD, FASCO, ASCO Past President and Pioneer of Hodgkin Lymphoma TreatmentSeptember 7th, 2022
Xilis Announces Breast Cancer Oncologist Dr. Daniel F. Hayes to Join Clinical Advisory BoardJune 8th, 2022
Join now to see all

Grant Support

Effects Of Exemestane Or Letrozole On Surrogate Markers Of ResponseNational Center For Research Resources2007
Pilot Trial Correlating Metabolic Profile Of Tamoxifen With HOT FlashesNational Center For Research Resources2004–2007
A Multi-Center Randomized Clinical Trial Correlating The Effects Of 24 Months OfNational Center For Research Resources2006
Correlative Studies Of Erbb-2/Her2 And P53 In Calgb PRO.National Cancer Institute2003–2005
Docetaxel (TAXOTERE) &Bcl-2-Antisense OligonucleotideNational Center For Research Resources2000
Phase 2 Clinical Trials Of Oltipraz In Breast NeoplasiaDivision Of Cancer Prevention And Control1999–2000
Cancer And Acute Leukemia Group B (CALGB) Inst GrantNational Cancer Institute1998–2000
Phase II Clinical Trial Of Dehydroepi-AndrosteroneDivision Of Cancer Prevention And Control1999
Correlative Studies Of Angiogenesis In Breast CancerNational Cancer Institute1996–1997
Correlative Studies Of Angiogenesis In Breast CancerNational Cancer Institute1994–1996
Circulating C-NEU Protein In Breast Cancer PatientsNational Cancer Institute1991–1992
Immunodiagnostic Approaches To Breast CancerNational Cancer Institute1985–1987